Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance biologics, raised $70 million by offering 5 million shares at $14. It had originally planned to raise $64 million by offering 4.25 million shares at $14 to $16....read more
All eyes are on communications tech IPO Twilio (TWLO). The reception of its offering will send a message to other tech unicorns that have been called out for...read more
Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance drugs, announced terms for its IPO on Wednesday. The Watertown, MA-based company plans to raise $64 million by offering 4.3 million shares at a price range of...read more
Selecta Biosciences, which is developing immunotherapies based on its proprietary nanoparticle platform, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
The Watertown, MA-based company was founded in 2007 and plans to...read more
Nanoparticle biotech Selecta Biosciences prices upsized IPO at $14, the low end of the range
Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance biologics, raised $70 million by offering 5 million shares at $14. It had originally planned to raise $64 million by offering 4.25 million shares at $14 to $16....read more
US IPO Week Ahead: IPO market discovers whether unicorns can fly with tech firm Twilio
All eyes are on communications tech IPO Twilio (TWLO). The reception of its offering will send a message to other tech unicorns that have been called out for...read more
Are nanoparticles the next big thing? Selecta Biosciences sets terms for $64 million IPO
Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance drugs, announced terms for its IPO on Wednesday. The Watertown, MA-based company plans to raise $64 million by offering 4.3 million shares at a price range of...read more
Think nano: Selecta Biosciences files for a $75 million IPO to fund nanoparticle immunotherapies
Selecta Biosciences, which is developing immunotherapies based on its proprietary nanoparticle platform, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering. The Watertown, MA-based company was founded in 2007 and plans to...read more